Brexpiprazole: a new leaf on the partial dopamine agonist branch

Australasian Psychiatry

Volumn 26, Issue 1, 2018, Pages 92-94

  Hope, Judy ^a   Castle, David ^b   Keks, Nicholas A ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

aripiprazole; brexpiprazole; depression; pharmacotherapy; schizophrenia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMFEBUTAMONE; ARIPIPRAZOLE; BREXPIPRAZOLE; CARBAMAZEPINE; CYTOCHROME P450 2D6; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; PAROXETINE; PROLACTIN; QUETIAPINE; SEROTONIN 2 AGONIST; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

AGITATION; AKATHISIA; ANTICHOLINERGIC EFFECT; ARTICLE; BODY WEIGHT GAIN; COGNITIVE DEFECT; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYMPTOMSCHIZOPHRENIA; HEADACHE; HUMAN; INSOMNIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MOOD DISORDER; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; SCHIZOPHRENIA; TREATMENT RESISTANT DEPRESSION; COMPARATIVE STUDY;

ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOPAMINE AGONISTS; HUMANS; QUINOLONES; SCHIZOPHRENIA; THIOPHENES;

EID: 85041737870     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1177/1039856217732473     Document Type: Article

References (16)

1. Stahl S., Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectrums 2016; 21: 1–6.
2. Leucht S, Cipriani A, Spineli L. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951–962.
3. Keks N, Hope J, Culhane C., Aripiprazole long-acting injection: promising but more evidence needed. Australas Psych 2016; 24: 368–370.
4. Lundbeck Australia. REXULTI (Brexpiprazole) product information. North Ryde, 2017.
5. Garnock-Jones K., Brexpiprazole: a review in schizophrenia. CNS Drugs 2016; 30: 335–342.
6. Das S, Barnwal P, Winston A. Brexpiprazole: so far so good. Ther Adv Psychopharmacol 2016; 6: 39–54.
7. 2A receptors. Eur Neuropsychopharmacol 2015; 25: 505–11.
8. Correll CU, Skuban A, Ouyang J. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 1, 72: 870–880.
9. Kane JM, Skuban A, Ouyang J. A multicentre, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015; 164: 127–135.
10. Fleischhacker WW, Hobart M, Ouyang J. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomised, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2017; 20: 11–21.
11. Citrome L, Ota A, Nagamizu K. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharm 2016; 31: 192–201.
12. Marder S, Hakalam, Gislum A.. An interventional, multi-centre, randomized, double-blind, placebo-controlled, active reference, flexible dose study of brexpiprazole in adults with acute schizophrenia. Eur Psychiatry 2016; 33: S99.
13. Thase M, Youakim J, Skuban A. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; 76: 1224–1231.
14. Thase M, Youakim J, Skuban A. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015; 76:1232–1240.
15. McIntyre R, Weiller E, Zhang P. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials. J Affect Disord 2016; 201: 116–123.
16. Citrome L., The ABC’s of dopamine partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15 minute challenge to sort these agents out. Int J Clin Pract 2015; 69: 1211–1220.